




ELSEVIER

Contents lists available at ScienceDirect

Atherosclerosis

journal homepage: www.elsevier.com/locate/atherosclerosis

Conference report

A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC)^{*,**,***}

ARTICLE INFO

Keywords:

Familial hypercholesterolemia
International symposium

Topics covered:

- Familial hypercholesterolemia (FH): genetic, diagnostic criteria and prevalence
- Lp (a) in FH, its role in the development of atherosclerotic disease
- PCSK9: from biology to pharmacology
- LDL: apheresis and statins in treatment of FH

Bishkek (Kyrgyzstan) hosted the International Symposium ‘Medicine of the Silk Road’. This Symposium was attended by leading specialists of the European and International Atherosclerosis Societies, Kyrgyzstan and Russia. More than 400 physicians from all regions of Kyrgyzstan had the opportunity to get familiar with the trends and advancements in modern medicine. Within the framework of the Symposium, the three joint sessions of the KSC with the IAS and EAS were dedicated to the problem of diagnosis and treatment of familial hypercholesterolemia (FH).

At one of such sessions, Professor M. Snejdrlava shared her experience on the identification of patients with this genetic pathology in the Czech Republic. Professor S.N. Pokrovsky from Russia highlighted the role of Lp(a) in the development of coronary heart disease and

atherosclerosis of peripheral arteries. Furthermore, at the joint session, together with specialists from the EAS, the issues related to the treatment of hyperlipidaemia were discussed, and Professor G.D. Norata from Italy presented a very interesting report on the role of PCSK9 in the development of lipid metabolism disorders, and elaborated on the results of studies using PCSK9 inhibitors in clinical practice. Moreover, the new perspectives in gene therapy of PCSK9, and the up-to-date results of research on the reduction of atherogenic lipids were also discussed.

In addition, given the great interest in the treatment of lipid metabolism disorders, the Symposium guests presented practical lectures for Kyrgyzstan doctors on the use of low density lipoprotein (LDL) apheresis in the treatment of patients with FH, and the role of statins in the treatment of dyslipidaemia, where once again the importance of achieving target levels for LDL-cholesterol to improve prognosis was emphasised.

The local physicians appreciated the International Symposium ‘Medicine of the Silk Road’ conducted as part of the family hypercholesterolemia week in Kyrgyzstan, and they expressed their wishes to carry out such annual joint meetings with the European and International Atherosclerosis Societies (Fig. 1).

* Name of the conference: The International Symposium ‘Medicine of the Silk Road’, The Kyrgyz Society of Cardiology (KSC) with the participation of the EAS, IAS and ESC.

** Dates and venue: October 2–3, 2018, Bishkek, Kyrgyzstan.

*** President of the conference: Erkin M. Mirrakhimov

<https://doi.org/10.1016/j.atherosclerosis.2018.11.036>

Received 21 November 2018; Accepted 29 November 2018

Available online 03 December 2018

0021-9150



Prof. Norata G.B. (Italy)

Prof. Mirrakhimov E.M. (Kyrgyzstan),
Prof. Snejdrlva M. (Czech Republic)

Prof. Pokrovsky S.N. (Russia)

Fig. 1. Participants in the symposium.

Conflict of interest

The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

Olga S. Lunegova, Erkin M. Mirrakhimov
Togolok Moldo 3, Bishkek, Kyrgyzstan
E-mail address: olga.lunegova@gmail.com (O.S. Lunegova).